<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Medical Devices on DEX Research</title><link>https://thedexs.com/tags/medical-devices/</link><description>Recent content in Medical Devices on DEX Research</description><generator>Hugo -- gohugo.io</generator><language>en</language><lastBuildDate>Tue, 27 Oct 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://thedexs.com/tags/medical-devices/index.xml" rel="self" type="application/rss+xml"/><item><title>Global Healthcare Industry Report</title><link>https://thedexs.com/post/healthcare-industry-report/</link><pubDate>Tue, 27 Oct 2026 00:00:00 +0000</pubDate><guid>https://thedexs.com/post/healthcare-industry-report/</guid><description>&lt;img src="https://thedexs.com/post/healthcare-industry-report/assets/cover.webp" alt="Featured image of post Global Healthcare Industry Report" /&gt;&lt;p class="research-preview-note"&gt;Industry report · Version 1.1 · Published: 27 October 2026 · Research cutoff: 26 October 2026.&lt;/p&gt;
&lt;p class="research-figure-caption"&gt;Cover: AI-generated concept image of a hospital and IV bag. It does not depict Baxter, North Cove or the hurricane.&lt;/p&gt;
&lt;p class="research-downloads"&gt;&lt;a href="assets/report-en.txt" download&gt;English manuscript&lt;/a&gt; · &lt;a href="assets/evidence-en.json" download&gt;Evidence records&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;A global industry framework with quantitative case studies from the United States and China. This is an industry overview; its quantitative findings do not represent every region or healthcare submarket. The industry boundary includes medicines, medical devices and diagnostics, research and manufacturing services, distribution, clinical care and payment. Consumer wellness, beauty products and general fitness are excluded. Research cutoff is 26 October 2026. Data periods differ and are identified locally. The global spending figure is an explicitly historical 2022 baseline, not the latest GHED observation or a 2026 market estimate.&lt;/p&gt;
&lt;p&gt;DEX assessment: durable commercial value is most likely where a business can demonstrate clinical usefulness, obtain a workable payment route and deliver reliably. More demand or a larger revenue base alone does not establish stronger profits. The analysis below separates observed facts from mechanisms and research hypotheses.&lt;/p&gt;
&lt;h2 id="part-1-industry-story"&gt;&lt;a href="#part-1-industry-story" class="header-anchor"&gt;&lt;/a&gt;Part 1: Industry Story
&lt;/h2&gt;&lt;h3 id="a-factory-interruption-reaches-the-bedside"&gt;&lt;a href="#a-factory-interruption-reaches-the-bedside" class="header-anchor"&gt;&lt;/a&gt;A factory interruption reaches the bedside
&lt;/h3&gt;&lt;p&gt;In late September 2024, Hurricane Helene flooded Baxter&amp;#x27;s North Cove manufacturing facility in North Carolina. On 12 October, the US Centers for Disease Control and Prevention issued a health advisory about disruption to intravenous and peritoneal dialysis solutions from the site. The advisory warned that patient care could be affected and called on healthcare organizations to assess supplies and plan mitigation. [&lt;a class="evidence-cite" href="#source-E01" aria-label="Source E01"&gt;E01&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E03" aria-label="Source E03"&gt;E03&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The regulatory response shows how a manufacturing problem becomes a clinical and institutional problem. On 11 October 2024, the FDA said three additional products were in inadequate national supply: 70% dextrose IV solution, lactated Ringer&amp;#x27;s IV solution and peritoneal dialysis solution. Baxter later reported that the plant had regained pre-hurricane production levels in February 2025; its 13 May 2025 update said inventory had recovered and allocations had been removed for virtually all North Cove IV solution codes. Those statements describe different stages of recovery. They do not establish that every hospital or every fluid product normalized on the same date. [&lt;a class="evidence-cite" href="#source-E02" aria-label="Source E02"&gt;E02&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E03" aria-label="Source E03"&gt;E03&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;An infusion fluid depends on more than its ingredients. The care pathway also needs validated manufacturing, packaging, regulatory release, transport, purchasing and clinicians who can administer it safely. If one essential input is unavailable, an otherwise well-equipped facility can lose usable treatment capacity. The industrial lesson is that the economic importance of an input can be much larger than its visible place in a hospital budget. That is DEX&amp;#x27;s interpretation of the incident, not a measured estimate of its financial losses.&lt;/p&gt;
&lt;p&gt;The case introduces the central question of this report: who creates a treatment, who gets it to the patient, and who pays for it? A patient may be the user while an insurer or government is the payer, and the hospital may choose the product. These roles create several separate decisions between technical invention and realized revenue. Those decisions shape which products get used and which businesses collect revenue.&lt;/p&gt;
&lt;h2 id="part-2-industry-value-chain"&gt;&lt;a href="#part-2-industry-value-chain" class="header-anchor"&gt;&lt;/a&gt;Part 2: Industry Value Chain
&lt;/h2&gt;&lt;h3 id="upstream-research-inputs-and-development-services"&gt;&lt;a href="#upstream-research-inputs-and-development-services" class="header-anchor"&gt;&lt;/a&gt;Upstream research inputs and development services
&lt;/h3&gt;&lt;p&gt;Upstream organizations supply the tools and evidence needed to create medical products. Research instruments, reagents and laboratory consumables help discover and characterize candidates. Clinical research services help design and execute studies, manage study data and prepare evidence. These suppliers sell mainly to pharmaceutical companies, biotechnology firms, research institutions and laboratories. Thermo Fisher Scientific is an illustrative supplier across both groups; its 2025 Form 10-K describes laboratory products, outsourced drug development, clinical research and commercial manufacturing, including the PPD and Patheon brands. [&lt;a class="evidence-cite" href="#source-E08" aria-label="Source E08"&gt;E08&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The commercial models differ. A reagent supplier may benefit from repeated orders after a workflow is established. An instrument supplier combines equipment sales with service and consumables. A contract research organization, or CRO, delivers projects and contracted services. As an analytical matter, recurring use can create switching costs, while dependence on a few customers or on research budgets can make demand uneven. Repeat purchasing is not automatically a subscription, and a signed development project is not a guarantee that the underlying medicine will succeed.&lt;/p&gt;
&lt;p&gt;A useful supplier investigation asks what must be revalidated if a customer switches, how much revenue comes from consumables rather than equipment, and how cancellations affect a backlog. These are diligence questions, not reported answers for every company. An upstream supplier may serve non-medical customers too, so its total corporate revenue should not be presented as pure healthcare revenue.&lt;/p&gt;
&lt;h3 id="midstream-manufacturing-medicines-and-medical-products"&gt;&lt;a href="#midstream-manufacturing-medicines-and-medical-products" class="header-anchor"&gt;&lt;/a&gt;Midstream manufacturing medicines and medical products
&lt;/h3&gt;&lt;p&gt;The midstream converts knowledge and materials into regulated, usable products. We place contract development and manufacturing organizations, or CDMOs, here because they develop processes and manufacture drug substance or finished products. The boundary overlaps with upstream development services. Lonza is an example: its 2025 annual-report strategy section describes mammalian manufacturing, highly potent active pharmaceutical ingredients and drug-product capabilities. The document also reports customer agreements and the integration of its Vacaville site. These disclosures demonstrate activity; they do not establish a supply contract between Lonza and every medicine company shown in our map. [&lt;a class="evidence-cite" href="#source-E09" aria-label="Source E09"&gt;E09&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Medicine developers earn revenue through product sales and, depending on the contract, collaboration payments, royalties or milestones. Lilly&amp;#x27;s Mounjaro and Zepbound are concrete product examples. For this group, clinical differentiation must survive manufacturing scale-up and the buyer&amp;#x27;s coverage decision. Intellectual property and clinical evidence can support commercial protection, while competition, patent expiry and net-price changes can erode it. These mechanisms should be assessed at the product and indication level. [&lt;a class="evidence-cite" href="#source-E10" aria-label="Source E10"&gt;E10&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Diagnostics and medical devices turn physical measurements or interventions into clinical decisions and treatment. Siemens Healthineers illustrates imaging, diagnostics and therapy-related equipment; its November 2025 strategy announcement described a new Precision Therapy grouping. Medtronic&amp;#x27;s current company facts describe cardiovascular, medical surgical and neuroscience portfolios. Baxter illustrates infusion products. These are business examples, not a ranked list of the largest suppliers. [&lt;a class="evidence-cite" href="#source-E03" aria-label="Source E03"&gt;E03&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E11" aria-label="Source E11"&gt;E11&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E12" aria-label="Source E12"&gt;E12&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Equipment economics depend on what happens after installation. Training, maintenance, compatibility and recurring consumables can matter as much as the initial sale. For a diagnostic system, a reader should check whether an additional test creates incremental reagent revenue and whether the hospital can obtain payment for that test. For an implant or surgical device, procedure volumes and clinical adoption matter. A machine installed, a product cleared for a particular use and a reimbursed procedure are three different milestones.&lt;/p&gt;
&lt;p&gt;CDMO capacity also needs careful interpretation. A new facility can expand potential output, but revenue depends on qualification, customer programs, operating utilization and contract terms. Construction announcements should not be converted directly into current sales. Likewise, a manufacturing contract or a company&amp;#x27;s description of its capabilities does not establish the clinical effectiveness of a product.&lt;/p&gt;
&lt;h3 id="downstream-distribution-care-and-payment"&gt;&lt;a href="#downstream-distribution-care-and-payment" class="header-anchor"&gt;&lt;/a&gt;Downstream distribution care and payment
&lt;/h3&gt;&lt;p&gt;Distribution connects manufacturers with pharmacies and care providers. McKesson&amp;#x27;s fiscal 2026 Form 10-K describes its North American Pharmaceutical business as providing distribution and logistics for branded, generic, specialty, biosimilar and over-the-counter medicines. Hospitals, pharmacies and other customers buy availability, purchasing and distribution capability as well as the physical product. Inventory financing, customer credit and the economics of a distribution contract therefore belong in the analysis. [&lt;a class="evidence-cite" href="#source-E13" aria-label="Source E13"&gt;E13&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Clinical providers combine staff, facilities, equipment, drugs and consumables into care. HCA Healthcare is a hospital and outpatient-services example. At this stage, useful operating measures include admissions, case mix, utilization, staffing expense and collections. Capacity has to be staffed and supplied to be usable. A provider can face higher revenue alongside higher labor or input costs, so activity and profit need separate examination. [&lt;a class="evidence-cite" href="#source-E14" aria-label="Source E14"&gt;E14&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Payment runs across the value chain even though the map places it next to downstream demand. Governments, insurance arrangements, employers and households finance care. UnitedHealthcare and Optum illustrate the overlap between insurance and healthcare services within one group. A payer influences access through coverage, networks, prices and payment rules; it is not simply another manufacturer selling a treatment. Patients may also pay directly, and not all care has insurance coverage. [&lt;a class="evidence-cite" href="#source-E05" aria-label="Source E05"&gt;E05&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E15" aria-label="Source E15"&gt;E15&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The chain is therefore an editorial organization of functions, not a sequence of verified contracts. Thermo Fisher spans research, development, diagnostics and manufacturing services; Optum spans services and care-related functions. Representative companies may appear across functions. The connecting lines in Figure 1 show classification only and must not be read as ownership, customer or supplier relationships.&lt;/p&gt;
&lt;figure id="industry-map-healthcare-value-chain" class="article-visual" data-visual="map" data-vendor="/vendor/article-visuals/markmap.js" aria-labelledby="industry-map-healthcare-value-chain-0-title"&gt;
 &lt;header class="visual-header"&gt;
 &lt;p class="visual-eyebrow"&gt;INDUSTRY MAP&lt;/p&gt;
 &lt;h3 id="industry-map-healthcare-value-chain-0-title"&gt;From research inputs to delivered care&lt;/h3&gt;
 &lt;p&gt;A functional map of the healthcare industry with illustrative companies and products. Expand a category to see its company examples.&lt;/p&gt;
 &lt;/header&gt;
 &lt;div class="visual-toolbar" hidden aria-label="Mind map controls"&gt;
 &lt;button type="button" data-action="fit"&gt;Fit to view&lt;/button&gt;
 &lt;button type="button" data-action="expand"&gt;Expand all&lt;/button&gt;
 &lt;button type="button" data-action="collapse"&gt;Collapse&lt;/button&gt;
 &lt;button type="button" data-action="fullscreen"&gt;Full screen&lt;/button&gt;
 &lt;/div&gt;
 &lt;div class="visual-stage" hidden aria-label="From research inputs to delivered care; a text outline is available below"&gt;&lt;/div&gt;
 &lt;p class="visual-status" role="status" aria-live="polite"&gt;&lt;/p&gt;
 &lt;details class="visual-fallback" open&gt;
 &lt;summary&gt;Read the full text outline&lt;/summary&gt;
 &lt;ul class="visual-outline"&gt;&lt;li&gt;&lt;span&gt;Global healthcare&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Upstream / Research and evidence&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Research tools&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Thermo Fisher Scientific — reagents and laboratory instruments [E08]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Clinical research&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Thermo Fisher Scientific PPD — clinical development services [E08]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Midstream / Manufacturing and medical products&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Contract manufacturing&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Lonza — drug substance and drug product [E09]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Medicines&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Lilly — Mounjaro and Zepbound [E10]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Diagnostics and imaging&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Siemens Healthineers — imaging, diagnostics and therapy [E11]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Devices and fluids&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Medtronic — medical devices [E12]&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Baxter — IV solutions [E03]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Downstream / Distribution, care and payment&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Distribution&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;McKesson — pharmaceutical distribution [E13]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Care delivery&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;HCA Healthcare — clinical care [E14]&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Optum — clinical and care services [E15]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Payment&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;UnitedHealthcare — health insurance [E15]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;
 &lt;/details&gt;
 &lt;figcaption class="visual-caption"&gt;
 &lt;p&gt;Figure 1. Connections show functional categories, not verified supply contracts, customers or ownership. Company examples are non-exhaustive and unranked. Companies may span functions; Optum also illustrates overlap within UnitedHealth Group. Source IDs resolve in the evidence appendix.&lt;/p&gt;
 &lt;p&gt;Sources: &lt;a href="https://thedexs.com/post/healthcare-industry-report/#appendix-evidence-and-methods"&gt;Evidence and methods: E03 and E08–E15&lt;/a&gt;. Reviewed 2026-10-26.&lt;/p&gt;
 &lt;/figcaption&gt;
 &lt;script class="visual-data" type="application/json"&gt;{"description":"A functional map of the healthcare industry with illustrative companies and products. Expand a category to see its company examples.","note":"Figure 1. Connections show functional categories, not verified supply contracts, customers or ownership. Company examples are non-exhaustive and unranked. Companies may span functions; Optum also illustrates overlap within UnitedHealth Group. Source IDs resolve in the evidence appendix.","reviewed":"2026-10-26","root":{"children":[{"children":[{"children":[{"name":"Thermo Fisher Scientific — reagents and laboratory instruments [E08]"}],"name":"Research tools"},{"children":[{"name":"Thermo Fisher Scientific PPD — clinical development services [E08]"}],"name":"Clinical research"}],"name":"Upstream / Research and evidence"},{"children":[{"children":[{"name":"Lonza — drug substance and drug product [E09]"}],"name":"Contract manufacturing"},{"children":[{"name":"Lilly — Mounjaro and Zepbound [E10]"}],"name":"Medicines"},{"children":[{"name":"Siemens Healthineers — imaging, diagnostics and therapy [E11]"}],"name":"Diagnostics and imaging"},{"children":[{"name":"Medtronic — medical devices [E12]"},{"name":"Baxter — IV solutions [E03]"}],"name":"Devices and fluids"}],"name":"Midstream / Manufacturing and medical products"},{"children":[{"children":[{"name":"McKesson — pharmaceutical distribution [E13]"}],"name":"Distribution"},{"children":[{"name":"HCA Healthcare — clinical care [E14]"},{"name":"Optum — clinical and care services [E15]"}],"name":"Care delivery"},{"children":[{"name":"UnitedHealthcare — health insurance [E15]"}],"name":"Payment"}],"name":"Downstream / Distribution, care and payment"}],"name":"Global healthcare"},"sources":[{"title":"Evidence and methods: E03 and E08–E15","url":"/post/healthcare-industry-report/#appendix-evidence-and-methods"}],"title":"From research inputs to delivered care"}&lt;/script&gt;
&lt;/figure&gt;

&lt;h2 id="part-3-market-landscape"&gt;&lt;a href="#part-3-market-landscape" class="header-anchor"&gt;&lt;/a&gt;Part 3: Market Landscape
&lt;/h2&gt;&lt;h3 id="measure-spending-before-assigning-market-shares"&gt;&lt;a href="#measure-spending-before-assigning-market-shares" class="header-anchor"&gt;&lt;/a&gt;Measure spending before assigning market shares
&lt;/h3&gt;&lt;p&gt;Healthcare spending provides a scale reference, but it is not the sum of all healthcare-company revenues. A medicine can appear in manufacturer sales, distributor revenue and a final care bill. Adding those transactions can count the same economic flow several times. Insurer revenue also includes funds subsequently paid to providers. A meaningful market-share denominator must specify the country, period, product or service, and whether the measure is expenditure, revenue, units or enrollment.&lt;/p&gt;
&lt;p&gt;The WHO&amp;#x27;s 2024 expenditure report records US$9.8 trillion of global current health expenditure in 2022. This is a historical scale reference, excludes health capital expenditure and is not a 2026 estimate. The US CMS national accounts record US$5,278.6 billion of national health expenditure in 2024, up 7.2%, including investment. China&amp;#x27;s official 2025 statistical bulletin gives a preliminary estimate of CNY9,336.72 billion of total health expenditure. Those measures differ in year, currency and accounting boundary; they are not combined into a global league table or used to calculate a US share of the world. [&lt;a class="evidence-cite" href="#source-E04" aria-label="Source E04"&gt;E04&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E05" aria-label="Source E05"&gt;E05&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E06" aria-label="Source E06"&gt;E06&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;A forecast is another category of evidence. A population projection or anticipated budget path can inform a scenario, but it is not an observed sale. The differing statistical boundaries do not support a single compound growth rate covering every healthcare business in this edition. Segment-level research should choose a consistent dataset before calculating historical growth, and should retain revisions and changes in definitions.&lt;/p&gt;
&lt;h3 id="care-delivery-accounts-for-much-of-the-us-spending-base"&gt;&lt;a href="#care-delivery-accounts-for-much-of-the-us-spending-base" class="header-anchor"&gt;&lt;/a&gt;Care delivery accounts for much of the US spending base
&lt;/h3&gt;&lt;p&gt;Figure 2 uses one denominator throughout: US national health expenditure in calendar 2024. Hospital care was US$1,634.7 billion, physician and clinical services US$1,109.7 billion, and retail prescription drugs US$467.0 billion. Together, hospital and physician/clinical services represented about 52.0% of the total. The chart&amp;#x27;s remaining category is the residual after the three named categories and includes other care, administration, public health and investment. This is an expenditure composition, not supplier market shares. [&lt;a class="evidence-cite" href="#source-E05" aria-label="Source E05"&gt;E05&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Retail prescription drugs are a narrower category than all medicines used in the health system. Products used within hospital and other service settings can be included in the relevant service expenditure. Treating the retail figure as total pharmaceutical demand would misread the accounts. Similarly, national hospital spending cannot be used as the denominator for a multinational provider&amp;#x27;s total revenue without adjusting geography and included services.&lt;/p&gt;
&lt;p&gt;DEX interpretation: service capacity, clinical workflows and payment operations deserve attention alongside new drug launches. A technology supplier&amp;#x27;s opportunity depends partly on whether its customer has the staff, workflow and budget to use the technology. The spending chart establishes where recorded expenditure sits; it does not by itself establish how profitable a supplier will be.&lt;/p&gt;
&lt;figure id="market-share-healthcare-us-expenditure-2024" class="article-visual" data-visual="share" data-vendor="/vendor/article-visuals/echarts.js" aria-labelledby="market-share-healthcare-us-expenditure-2024-1-title"&gt;
 &lt;header class="visual-header"&gt;
 &lt;p class="visual-eyebrow"&gt;EXPENDITURE COMPOSITION · Calendar 2024&lt;/p&gt;
 &lt;h3 id="market-share-healthcare-us-expenditure-2024-1-title"&gt;Where US healthcare expenditure goes&lt;/h3&gt;
 &lt;p&gt;National Health Expenditure Accounts: US$5,278.6 billion in 2024, including investment. This is expenditure composition, not supplier market share.&lt;/p&gt;
 &lt;p class="visual-meta"&gt;United States · Share of national health expenditure (%)&lt;/p&gt;
 &lt;/header&gt;
 &lt;div class="visual-toolbar" hidden aria-label="Chart controls"&gt;
 &lt;button type="button" data-action="fullscreen"&gt;Full screen&lt;/button&gt;
 &lt;/div&gt;
 &lt;div class="visual-stage" hidden aria-label="Where US healthcare expenditure goes; exact percentages are available in the table below"&gt;&lt;/div&gt;
 &lt;p class="visual-status" role="status" aria-live="polite"&gt;&lt;/p&gt;
 &lt;details class="visual-fallback" open&gt;
 &lt;summary&gt;View the data table&lt;/summary&gt;
 &lt;div class="table-wrapper"&gt;
 &lt;table class="visual-table"&gt;
 &lt;caption&gt;Where US healthcare expenditure goes · Calendar 2024 · Share of national health expenditure (%)&lt;/caption&gt;
 &lt;thead&gt;&lt;tr&gt;&lt;th scope="col"&gt;Expenditure category&lt;/th&gt;&lt;th scope="col"&gt;US$ million&lt;/th&gt;&lt;th scope="col"&gt;Share&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;
 &lt;tbody&gt;&lt;tr&gt;&lt;th scope="row"&gt;Hospital care&lt;/th&gt;&lt;td&gt;1,634,700&lt;/td&gt;&lt;td&gt;31.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Physician and clinical services&lt;/th&gt;&lt;td&gt;1,109,700&lt;/td&gt;&lt;td&gt;21.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Retail prescription drugs&lt;/th&gt;&lt;td&gt;467,000&lt;/td&gt;&lt;td&gt;8.8%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;All remaining NHE&lt;/th&gt;&lt;td&gt;2,067,200&lt;/td&gt;&lt;td&gt;39.2%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
 &lt;/table&gt;
 &lt;/div&gt;
 &lt;a class="visual-download" href="https://thedexs.com/data/charts/healthcare-us-expenditure-2024.csv" download&gt;Download data (CSV)&lt;/a&gt;
 &lt;/details&gt;
 &lt;figcaption class="visual-caption"&gt;
 &lt;p&gt;Figure 2. Slice areas use the published expenditure amounts converted from US$ billion to US$ million; labels are rounded to one decimal. Remaining NHE = 5,278.6 − 1,634.7 − 1,109.7 − 467.0 = US$2,067.2 billion, including other care, administration, public health and investment. Retail drugs exclude medicines recorded within service expenditure. Source E05.&lt;/p&gt;
 &lt;p&gt;Source: &lt;a href="https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet"&gt;US Centers for Medicare and Medicaid Services — [E05] National Health Expenditure Accounts Table 2 and NHE Fact Sheet&lt;/a&gt; (Fact sheet last modified 2026-06-24; table is the 1960 to 2024 historical release). Reviewed 2026-10-26.&lt;/p&gt;
 &lt;/figcaption&gt;
 &lt;script class="visual-data" type="application/json"&gt;{"center_label":"2024","dimension":"Expenditure category","eyebrow":"EXPENDITURE COMPOSITION","geography":"United States","metric":"Share of national health expenditure (%)","note":"Figure 2. Slice areas use the published expenditure amounts converted from US$ billion to US$ million; labels are rounded to one decimal. Remaining NHE = 5,278.6 − 1,634.7 − 1,109.7 − 467.0 = US$2,067.2 billion, including other care, administration, public health and investment. Retail drugs exclude medicines recorded within service expenditure. Source E05.","percentDecimals":1,"period":"Calendar 2024","reviewed":"2026-10-26","scope":"National Health Expenditure Accounts: US$5,278.6 billion in 2024, including investment. This is expenditure composition, not supplier market share.","series":[{"name":"Hospital care","units":1634700,"value":31},{"name":"Physician and clinical services","units":1109700,"value":21},{"name":"Retail prescription drugs","units":467000,"value":8.8},{"name":"All remaining NHE","units":2067200,"value":39.2}],"source":{"locator":"Table 2 Amount in Billions 2024 column rows 4 7 9 and 16; Fact Sheet Historical NHE 2024","published":"Fact sheet last modified 2026-06-24; table is the 1960 to 2024 historical release","publisher":"US Centers for Medicare and Medicaid Services","title":"[E05] National Health Expenditure Accounts Table 2 and NHE Fact Sheet","url":"https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet"},"title":"Where US healthcare expenditure goes","totalUnits":5278600,"unit":"%","unitsColumnLabel":"US$ million","unitsLabel":"US$ million"}&lt;/script&gt;
&lt;/figure&gt;

&lt;h3 id="a-defined-insurance-submarket-shows-concentration"&gt;&lt;a href="#a-defined-insurance-submarket-shows-concentration" class="header-anchor"&gt;&lt;/a&gt;A defined insurance submarket shows concentration
&lt;/h3&gt;&lt;p&gt;Medicare Advantage, also called Medicare Part C, provides Medicare benefits through approved private health plans, generally combining hospital, medical and prescription drug coverage. It is one part of US Medicare. The following figure excludes Original Medicare and does not describe the entire employer-insurance market. [&lt;a class="evidence-cite" href="#source-E22" aria-label="Source E22"&gt;E22&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Figure 3 is deliberately limited to US Medicare Advantage enrollment in March 2026. KFF&amp;#x27;s own analysis of CMS administrative data reports shares of 26% for UnitedHealth Group, 20% for Humana, 12% for CVS Health, 6% for Kaiser Foundation Health Plan and 5% for Elevance Health. Our displayed remainder is 31%, calculated from those published rounded percentages. It is not a global healthcare share, a revenue share or a measure of clinical quality. [&lt;a class="evidence-cite" href="#source-E07" aria-label="Source E07"&gt;E07&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Enrollment concentration can affect the negotiating setting for providers and suppliers, but national shares do not describe every county or provider network. A company can seek a different balance of membership, premium income and medical costs. Scale therefore needs to be interpreted together with benefit design, geographic coverage and the cost of serving members. This is a commercial mechanism, not a claim that the largest plan necessarily delivers better care.&lt;/p&gt;
&lt;figure id="market-share-healthcare-us-medicare-advantage-mar-2026" class="article-visual" data-visual="share" data-vendor="/vendor/article-visuals/echarts.js" aria-labelledby="market-share-healthcare-us-medicare-advantage-mar-2026-2-title"&gt;
 &lt;header class="visual-header"&gt;
 &lt;p class="visual-eyebrow"&gt;ENROLLMENT SHARE · March 2026&lt;/p&gt;
 &lt;h3 id="market-share-healthcare-us-medicare-advantage-mar-2026-2-title"&gt;Medicare Advantage enrollment shares&lt;/h3&gt;
 &lt;p&gt;US Medicare Advantage enrollment by parent organization, excluding Original Medicare. This is one insurance submarket, not all US insurance or global healthcare.&lt;/p&gt;
 &lt;p class="visual-meta"&gt;United States · Share of Medicare Advantage enrollees (%)&lt;/p&gt;
 &lt;/header&gt;
 &lt;div class="visual-toolbar" hidden aria-label="Chart controls"&gt;
 &lt;button type="button" data-action="fullscreen"&gt;Full screen&lt;/button&gt;
 &lt;/div&gt;
 &lt;div class="visual-stage" hidden aria-label="Medicare Advantage enrollment shares; exact percentages are available in the table below"&gt;&lt;/div&gt;
 &lt;p class="visual-status" role="status" aria-live="polite"&gt;&lt;/p&gt;
 &lt;details class="visual-fallback" open&gt;
 &lt;summary&gt;View the data table&lt;/summary&gt;
 &lt;div class="table-wrapper"&gt;
 &lt;table class="visual-table"&gt;
 &lt;caption&gt;Medicare Advantage enrollment shares · March 2026 · Share of Medicare Advantage enrollees (%)&lt;/caption&gt;
 &lt;thead&gt;&lt;tr&gt;&lt;th scope="col"&gt;Parent organization&lt;/th&gt;&lt;th scope="col"&gt;Share&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;
 &lt;tbody&gt;&lt;tr&gt;&lt;th scope="row"&gt;UnitedHealth Group&lt;/th&gt;&lt;td&gt;26%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Humana&lt;/th&gt;&lt;td&gt;20%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;CVS Health&lt;/th&gt;&lt;td&gt;12%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Kaiser Foundation Health Plan&lt;/th&gt;&lt;td&gt;6%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Elevance Health&lt;/th&gt;&lt;td&gt;5%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;All remaining organizations&lt;/th&gt;&lt;td&gt;31%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
 &lt;/table&gt;
 &lt;/div&gt;
 &lt;a class="visual-download" href="https://thedexs.com/data/charts/healthcare-us-medicare-advantage-mar-2026.csv" download&gt;Download data (CSV)&lt;/a&gt;
 &lt;/details&gt;
 &lt;figcaption class="visual-caption"&gt;
 &lt;p&gt;Figure 3. Published rounded KFF shares based on CMS enrollment files. Remaining organizations = 100 − 26 − 20 − 12 − 6 − 5 = 31%; this residual inherits source rounding and is not an independently measured exact share. DEX did not reaggregate CMS enrollment microdata. Shares do not measure revenue or clinical quality. Source E07.&lt;/p&gt;
 &lt;p&gt;Source: &lt;a href="https://www.kff.org/medicare/medicare-advantage-in-2026-enrollment-update-and-key-trends/"&gt;KFF — [E07] Medicare Advantage in 2026: Enrollment Update and Key Trends&lt;/a&gt; (2026-06-05). Reviewed 2026-10-26.&lt;/p&gt;
 &lt;/figcaption&gt;
 &lt;script class="visual-data" type="application/json"&gt;{"center_label":"MAR 2026","dimension":"Parent organization","eyebrow":"ENROLLMENT SHARE","geography":"United States","metric":"Share of Medicare Advantage enrollees (%)","note":"Figure 3. Published rounded KFF shares based on CMS enrollment files. Remaining organizations = 100 − 26 − 20 − 12 − 6 − 5 = 31%; this residual inherits source rounding and is not an independently measured exact share. DEX did not reaggregate CMS enrollment microdata. Shares do not measure revenue or clinical quality. Source E07.","percentDecimals":0,"period":"March 2026","reviewed":"2026-10-26","scope":"US Medicare Advantage enrollment by parent organization, excluding Original Medicare. This is one insurance submarket, not all US insurance or global healthcare.","series":[{"name":"UnitedHealth Group","value":26},{"name":"Humana","value":20},{"name":"CVS Health","value":12},{"name":"Kaiser Foundation Health Plan","value":6},{"name":"Elevance Health","value":5},{"name":"All remaining organizations","value":31}],"source":{"locator":"Section on enrollment concentration Figure 6 and its methods note","published":"2026-06-05","publisher":"KFF","title":"[E07] Medicare Advantage in 2026: Enrollment Update and Key Trends","url":"https://www.kff.org/medicare/medicare-advantage-in-2026-enrollment-update-and-key-trends/"},"title":"Medicare Advantage enrollment shares","unit":"%"}&lt;/script&gt;
&lt;/figure&gt;

&lt;h3 id="competition-and-profits-differ-across-functions"&gt;&lt;a href="#competition-and-profits-differ-across-functions" class="header-anchor"&gt;&lt;/a&gt;Competition and profits differ across functions
&lt;/h3&gt;&lt;p&gt;Competition in innovative medicines is organized around specific diseases, clinical outcomes and access. A diagnostic or device supplier competes through clinical performance, usability and its installed workflow. A distributor competes through purchasing, logistics and service reliability. A provider competes within a care network for clinical capability and patients, while a payer manages coverage and financial risk. These functions interact, but they should not be ranked on one unadjusted corporate-revenue chart.&lt;/p&gt;
&lt;p&gt;Three reported examples illustrate the difference. Lilly reported 2025 revenue of US$65.179 billion and net income of US$20.640 billion; HCA reported revenue of US$75.600 billion and net income attributable to HCA of US$6.784 billion; UnitedHealth Group reported revenue of US$447.6 billion and a 2.7% net margin. The first two corresponding income-to-revenue ratios are approximately 31.7% and 9.0%, calculated by DEX. They are company examples with different business scope and income attribution, not directly comparable segment margins or a representative industry average. [&lt;a class="evidence-cite" href="#source-E10" aria-label="Source E10"&gt;E10&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E14" aria-label="Source E14"&gt;E14&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E15" aria-label="Source E15"&gt;E15&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The medicine example also separates revenue growth from price increases. Lilly reported 45% revenue growth in 2025, with a disclosed breakdown of 50 percentage points from volume, minus 6 from price and plus 1 from foreign exchange, all rounded company figures. Mounjaro and Zepbound together contributed US$36.507 billion, about 56.0% of group revenue. That is corporate revenue concentration, not worldwide pharmaceutical market share. DEX assessment: growth quality requires examining the durability of volume, net-price changes and dependence on the main brands. [&lt;a class="evidence-cite" href="#source-E10" aria-label="Source E10"&gt;E10&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;McKesson offers another useful distinction: its North American Pharmaceutical segment reported a 1.09% operating profit margin for the fiscal year ended 31 March 2026. A high value of goods distributed can support very large revenue without a similarly large percentage margin. Segment operating profit is different from group net income. Researchers should retain the company&amp;#x27;s exact profit definition rather than compare that 1.09% directly with the net-income ratios above. [&lt;a class="evidence-cite" href="#source-E13" aria-label="Source E13"&gt;E13&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The practical lesson is to locate the source of economic protection. A supplier may rely on process validation, a medicine on clinical evidence and intellectual property, a hospital on local capacity and specialist teams, and a payer on contracting and risk management. Each protection has a failure mode: replacement products, a failed trial, reimbursement changes, staff shortages or a customer switching. Valuation requires evidence about that particular business rather than an assumed healthcare premium.&lt;/p&gt;
&lt;h3 id="china-and-ageing-change-the-research-questions"&gt;&lt;a href="#china-and-ageing-change-the-research-questions" class="header-anchor"&gt;&lt;/a&gt;China and ageing change the research questions
&lt;/h3&gt;&lt;p&gt;China&amp;#x27;s 2025 bulletin records 10.65 billion diagnosis and treatment visits across healthcare institutions, including 4.67 billion at hospitals. These are encounters, not unique patients. Within hospital visits in that same year, public hospitals recorded 3.93 billion and private hospitals 0.74 billion: approximately 84.2% and 15.8% respectively (Figure 4). The calculation uses published rounded visit totals; the shares do not measure revenue, profit or clinical quality. [&lt;a class="evidence-cite" href="#source-E06" aria-label="Source E06"&gt;E06&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The same bulletin lists 26,481 private hospitals out of 38,159 hospitals, about 69.4% by facility count. This is substantially above their share of visits. The measures describe different objects: the number of facilities and the volume of service activity. DEX assessment: counting hospitals alone does not establish their scale of care, and these shares do not by themselves establish differences in efficiency or quality. [&lt;a class="evidence-cite" href="#source-E06" aria-label="Source E06"&gt;E06&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Payment mechanisms also shape purchasing. The 2024 DRG/DIP explanation described case grouping and exceptional-case review. At its 2 September 2026 press conference, China&amp;#x27;s National Healthcare Security Administration announced version 3.0 and explained that payment standards use historical costs for patient groups. Savings from appropriate care can partly be retained under local arrangements, while the agency explicitly rejected requiring every case to remain below the standard. DEX assessment: suppliers need evidence about clinical value and delivery cost in the intended setting, alongside equipment installations and unit prices. Actual payment depends on the region, case and contract. [&lt;a class="evidence-cite" href="#source-E19" aria-label="Source E19"&gt;E19&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E23" aria-label="Source E23"&gt;E23&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The WHO projects that one in six people globally will be aged 60 or older by 2030. This supports investigating chronic care, rehabilitation and care coordination, but it does not establish a guaranteed revenue growth rate for any supplier. Need becomes commercial demand only when care is accessible, affordable and actually delivered. A useful research project follows that conversion rather than multiplying a population estimate by a product&amp;#x27;s advertised price. [&lt;a class="evidence-cite" href="#source-E18" aria-label="Source E18"&gt;E18&lt;/a&gt;]&lt;/p&gt;
&lt;figure id="market-share-healthcare-china-hospital-visits-2025" class="article-visual" data-visual="share" data-vendor="/vendor/article-visuals/echarts.js" aria-labelledby="market-share-healthcare-china-hospital-visits-2025-3-title"&gt;
 &lt;header class="visual-header"&gt;
 &lt;p class="visual-eyebrow"&gt;HOSPITAL ACTIVITY · 2025&lt;/p&gt;
 &lt;h3 id="market-share-healthcare-china-hospital-visits-2025-3-title"&gt;China hospital visits by ownership&lt;/h3&gt;
 &lt;p&gt;Public and private hospitals in China; denominator 4.67 billion hospital visits in 2025. This is hospital activity, not revenue, profit or care-quality share.&lt;/p&gt;
 &lt;p class="visual-meta"&gt;China · Share of hospital diagnosis and treatment visits (%)&lt;/p&gt;
 &lt;/header&gt;
 &lt;div class="visual-toolbar" hidden aria-label="Chart controls"&gt;
 &lt;button type="button" data-action="fullscreen"&gt;Full screen&lt;/button&gt;
 &lt;/div&gt;
 &lt;div class="visual-stage" hidden aria-label="China hospital visits by ownership; exact percentages are available in the table below"&gt;&lt;/div&gt;
 &lt;p class="visual-status" role="status" aria-live="polite"&gt;&lt;/p&gt;
 &lt;details class="visual-fallback" open&gt;
 &lt;summary&gt;View the data table&lt;/summary&gt;
 &lt;div class="table-wrapper"&gt;
 &lt;table class="visual-table"&gt;
 &lt;caption&gt;China hospital visits by ownership · 2025 · Share of hospital diagnosis and treatment visits (%)&lt;/caption&gt;
 &lt;thead&gt;&lt;tr&gt;&lt;th scope="col"&gt;Hospital ownership&lt;/th&gt;&lt;th scope="col"&gt;Million hospital visits&lt;/th&gt;&lt;th scope="col"&gt;Share&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;
 &lt;tbody&gt;&lt;tr&gt;&lt;th scope="row"&gt;Public hospitals&lt;/th&gt;&lt;td&gt;3,930&lt;/td&gt;&lt;td&gt;84.2%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Private hospitals&lt;/th&gt;&lt;td&gt;740&lt;/td&gt;&lt;td&gt;15.8%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
 &lt;/table&gt;
 &lt;/div&gt;
 &lt;a class="visual-download" href="https://thedexs.com/data/charts/healthcare-china-hospital-visits-2025.csv" download&gt;Download data (CSV)&lt;/a&gt;
 &lt;/details&gt;
 &lt;figcaption class="visual-caption"&gt;
 &lt;p&gt;Figure 4. Calculated from published rounded totals: public 39.3 and private 7.4, divided by 46.7, in units of 100 million hospital visits. Values are converted to millions for the table and slice areas; percentages are rounded to one decimal. Visits count encounters, not unique patients. Private hospitals account for 69.4% of facilities and 15.8% of visits; these describe different measures. Source E06.&lt;/p&gt;
 &lt;p&gt;Source: &lt;a href="https://wjw.shanxi.gov.cn/zfxxgk/fdzdgknr/ghjh/202608/P020260831335869219767.pdf"&gt;National Health Commission of China; official PDF hosted by Shanxi Health Commission — [E06] 2025年我国卫生健康事业发展统计公报 China Health Statistics Bulletin 2025&lt;/a&gt; (NHC release dated 2026-08-28; provincial PDF hosted August 2026). Reviewed 2026-10-26.&lt;/p&gt;
 &lt;/figcaption&gt;
 &lt;script class="visual-data" type="application/json"&gt;{"center_label":"2025","dimension":"Hospital ownership","eyebrow":"HOSPITAL ACTIVITY","geography":"China","metric":"Share of hospital diagnosis and treatment visits (%)","note":"Figure 4. Calculated from published rounded totals: public 39.3 and private 7.4, divided by 46.7, in units of 100 million hospital visits. Values are converted to millions for the table and slice areas; percentages are rounded to one decimal. Visits count encounters, not unique patients. Private hospitals account for 69.4% of facilities and 15.8% of visits; these describe different measures. Source E06.","percentDecimals":1,"period":"2025","reviewed":"2026-10-26","scope":"Public and private hospitals in China; denominator 4.67 billion hospital visits in 2025. This is hospital activity, not revenue, profit or care-quality share.","series":[{"name":"Public hospitals","units":3930,"value":84.2},{"name":"Private hospitals","units":740,"value":15.8}],"source":{"locator":"Printed page 1 hospital counts; page 6 Table 4; pages 7 to 8 hospital diagnosis and treatment visits and Table 5","published":"NHC release dated 2026-08-28; provincial PDF hosted August 2026","publisher":"National Health Commission of China; official PDF hosted by Shanxi Health Commission","title":"[E06] 2025年我国卫生健康事业发展统计公报 China Health Statistics Bulletin 2025","url":"https://wjw.shanxi.gov.cn/zfxxgk/fdzdgknr/ghjh/202608/P020260831335869219767.pdf"},"title":"China hospital visits by ownership","totalUnits":4670,"unit":"%","unitsColumnLabel":"Million hospital visits","unitsLabel":"million hospital visits"}&lt;/script&gt;
&lt;/figure&gt;

&lt;h2 id="part-4-industry-problems"&gt;&lt;a href="#part-4-industry-problems" class="header-anchor"&gt;&lt;/a&gt;Part 4: Industry Problems
&lt;/h2&gt;&lt;h3 id="affordability-constrains-effective-demand"&gt;&lt;a href="#affordability-constrains-effective-demand" class="header-anchor"&gt;&lt;/a&gt;Affordability constrains effective demand
&lt;/h3&gt;&lt;p&gt;The WHO and World Bank&amp;#x27;s 2025 monitoring report estimates that 4.6 billion people were not fully covered by essential health services in 2023, while 2.1 billion experienced financial hardship from out-of-pocket health spending in 2022. The years and populations differ; the figures should not be added. The report uses updated indicators, so comparisons with older headline estimates require a consistent series. Unmet need is therefore substantial, but it is not automatically a paying customer base. [&lt;a class="evidence-cite" href="#source-E16" aria-label="Source E16"&gt;E16&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;For suppliers, the commercial constraint is the gap between a clinically desirable treatment and a budget that can pay for it. For households, the same gap can delay or prevent access. Possible responses include better pooling of financial risk and evidence-based purchasing. Each response requires financing, implementation and monitoring. Lowering one price alone does not ensure that personnel, diagnostics and follow-up become available.&lt;/p&gt;
&lt;h3 id="workforce-capacity-limits-delivery"&gt;&lt;a href="#workforce-capacity-limits-delivery" class="header-anchor"&gt;&lt;/a&gt;Workforce capacity limits delivery
&lt;/h3&gt;&lt;p&gt;The WHO projects a shortfall of 11 million health workers by 2030, concentrated mostly in low- and lower-middle-income countries. Its workforce page also notes that unemployment can coexist with unmet needs where public systems cannot afford to employ trained people. The bottleneck therefore involves financing, distribution and retention as well as training. It should not be reduced to a universal shortage of doctors in every market. [&lt;a class="evidence-cite" href="#source-E17" aria-label="Source E17"&gt;E17&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;More equipment can leave throughput unchanged if there are too few trained staff to operate it or too little capacity for follow-up. Scheduling tools, appropriate task allocation and training can be investigated as productivity interventions. Their value should be measured through safely completed care and staff workload, with attention to who bears the extra work. A shorter documentation task is useful only if the time saved survives integration and checking.&lt;/p&gt;
&lt;h3 id="reliability-and-clinical-evidence-remain-costly"&gt;&lt;a href="#reliability-and-clinical-evidence-remain-costly" class="header-anchor"&gt;&lt;/a&gt;Reliability and clinical evidence remain costly
&lt;/h3&gt;&lt;p&gt;The Baxter interruption illustrates the exposure created when an essential input depends on a vulnerable production site. Additional qualified production, inventory and contingency planning can improve resilience, but each ties up resources. A purchaser choosing only the lowest quoted unit price may not be paying explicitly for reserve capacity. That is a procurement incentive to investigate, not proof that a specific purchasing contract caused this incident. [&lt;a class="evidence-cite" href="#source-E01" aria-label="Source E01"&gt;E01&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E02" aria-label="Source E02"&gt;E02&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-E03" aria-label="Source E03"&gt;E03&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;Clinical evidence has a separate cost and uncertainty. A product must demonstrate value for a defined use and population; results from one setting do not automatically transfer to another. For drugs, changes in treatment alternatives or net prices can change the commercial return even after development. For devices, real clinical workflow and training affect adoption. Procurement should compare the total cost of safe delivery with the relevant outcome, while recognizing that evidence collection and longer follow-up also require money and time.&lt;/p&gt;
&lt;h3 id="ai-authorization-does-not-establish-commercial-adoption"&gt;&lt;a href="#ai-authorization-does-not-establish-commercial-adoption" class="header-anchor"&gt;&lt;/a&gt;AI authorization does not establish commercial adoption
&lt;/h3&gt;&lt;p&gt;The FDA&amp;#x27;s AI-enabled medical-device list identifies devices authorized for marketing in the United States and links to device-specific entries. The agency explicitly says the list is not comprehensive. It is a record of identified authorizations, not a census of deployed systems, revenue, patients served or products proven to outperform clinicians in all settings. Counting entries and calling the result a market size would therefore be a category error. [&lt;a class="evidence-cite" href="#source-E20" aria-label="Source E20"&gt;E20&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;The FDA&amp;#x27;s 2026 discussion paper on generative-AI medical devices considers risk assessment, premarket evaluation and postmarket monitoring. The agency states that it is for discussion only and is neither draft nor final guidance. That status matters: an open policy discussion must not be described as a new binding rule or a general authorization for autonomous diagnosis. [&lt;a class="evidence-cite" href="#source-E21" aria-label="Source E21"&gt;E21&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;DEX&amp;#x27;s commercial test for an AI tool is specific: can a defined user complete a defined clinical or administrative task more safely or efficiently, after integration, human review and error handling? A credible evaluation should record performance on the intended population, the work transferred to staff, operating cost and the route to payment. Sales claims without that evidence remain hypotheses. A general-purpose model&amp;#x27;s impressive demonstration does not answer those questions.&lt;/p&gt;
&lt;h3 id="research-priorities-with-observable-tests"&gt;&lt;a href="#research-priorities-with-observable-tests" class="header-anchor"&gt;&lt;/a&gt;Research priorities with observable tests
&lt;/h3&gt;&lt;p&gt;The preceding evidence suggests three research directions rather than a universal promise of rapid growth. First, examine critical-supply reliability: compare qualification, delivery performance and the cost of reserve capacity. Second, examine care productivity: compare actual time released and safely completed care with the full implementation cost. Third, examine evidence and payment operations: compare error rates, turnaround times and collected payments before and after a clearly defined intervention.&lt;/p&gt;
&lt;p&gt;These are DEX research hypotheses, not measured market forecasts or recommendations to buy particular securities. For each opportunity, identify the budget owner, the purchasing decision, the contractual unit of revenue and an outcome that can be checked. An attractive healthcare business must connect a real patient or institutional need to an executable delivery model and a payment stream that can cover its costs.&lt;/p&gt;
&lt;p&gt;&lt;span id="supporting-evidence"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;h2 id="appendix-evidence-and-methods"&gt;&lt;a href="#appendix-evidence-and-methods" class="header-anchor"&gt;&lt;/a&gt;Appendix: Evidence and Methods
&lt;/h2&gt;&lt;p&gt;Reading the evidence. References E01 to E23 connect the body and figures to specific records. All sources were read on 26 October 2026. Government statistics and regulatory records establish reported measures or actions; company documents establish what the company disclosed. KFF supplies its own analysis of CMS enrollment data. DEX did not independently reaggregate the enrollment microdata. The 23 records are not 23 independent corroborations of the whole report; company disclosures support issuer-specific facts.&lt;/p&gt;
&lt;p&gt;Figure 2 calculation. Hospital 1634.7; physician and clinical services 1109.7; retail prescription drugs 467.0; all remaining NHE 2067.2; total 5278.6, all in US$ billion for calendar 2024. Residual = 5278.6 - 1634.7 - 1109.7 - 467.0. Each share = category / 5278.6 × 100, displayed to one decimal: 31.0%, 21.0%, 8.8%, 39.2%. Unrounded shares sum to 100%. Hospital plus physician/clinical = 51.99%, displayed as 52.0%. The chart shows uses of expenditure; no corporate revenue is added to the total.&lt;/p&gt;
&lt;p&gt;Figure 3 calculation. US Medicare Advantage enrollment in March 2026, by parent organization: UnitedHealth Group 26%; Humana 20%; CVS Health 12%; Kaiser Foundation Health Plan 6%; Elevance Health 5%. Other = 100 - 26 - 20 - 12 - 6 - 5 = 31%. Leading values are published rounded shares. The residual retains their rounding and is not an independently measured exact share. This figure does not show all US insurance, worldwide insurance or healthcare revenue.&lt;/p&gt;
&lt;p&gt;Figure 4 calculation. China hospital visits in 2025: public 39.3 and private 7.4, denominator 46.7, in units of 100 million visits. Shares are 84.1542% and 15.8458%, displayed as 84.2% and 15.8%. These are calculated from already rounded official visit totals. Separately, private hospitals were 26481 / 38159 × 100 = 69.3965% of hospital facilities, displayed as 69.4%. Facility counts and visit shares measure different objects and are not combined into one pie.&lt;/p&gt;
&lt;p&gt;Company calculations. Lilly 20640 / 65179 × 100 = 31.67%, displayed 31.7%; HCA 6784 / 75600 × 100 = 8.97%, displayed 9.0%. The numerators are net income and net income attributable to HCA respectively. UnitedHealth Group 2.7% is the company-reported net margin. McKesson 1.09% is its reported North American Pharmaceutical segment operating profit margin for the year ended 31 March 2026. These profit definitions and business scopes are not harmonized for a ranking.&lt;/p&gt;
&lt;p&gt;Product concentration calculation. Lilly Mounjaro 22965 plus Zepbound 13542 = US$36507 million; 36507 / 65179 × 100 = 56.0104%, displayed as 56.0% of Lilly group revenue in 2025. This does not calculate a global drug-market share. The 50, minus 6 and plus 1 revenue-growth components are the rounded decomposition reported by the company, not an independently estimated causal model.&lt;/p&gt;
&lt;p&gt;Units and uncertainty. One Chinese yi is 100 million: CNY93367.2 yi = CNY9336.72 billion, or CNY9.33672 trillion. China 2025 expenditure is a preliminary estimate. Diagnosis and treatment visits are encounters. Workforce and ageing figures are projections. No current global market size or unified healthcare CAGR is extrapolated from the older WHO baseline.&lt;/p&gt;
&lt;p&gt;Limits of this edition. Global coverage is functional rather than an exhaustive country survey. Detailed rules differ by jurisdiction. The 2026 DRG/DIP announcement updates the historical 2024 example, but national explanations do not replace current local reimbursement schedules. DEX hypotheses about procurement incentives, commercial protection and productivity are marked as interpretation and remain to be tested. No unread paid market report or search snippet is treated as verified evidence.&lt;/p&gt;
&lt;p&gt;Design references. The DEX cybersecurity article opening, value-chain map, market-share component, source notes and cover were inspected; the semiconductor article was also read for scope and citation practice. These pages guide presentation only and supply no healthcare facts. Exact references follow.&lt;/p&gt;
&lt;p&gt;&lt;a href="https://thedexs.com/post/cybersecurity-industry-report/" target="_blank" rel="noopener"&gt;https://thedexs.com/post/cybersecurity-industry-report/&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href="https://thedexs.com/post/semiconductor-industry-report/" target="_blank" rel="noopener"&gt;https://thedexs.com/post/semiconductor-industry-report/&lt;/a&gt;&lt;/p&gt;
&lt;section class="research-evidence" id="source-E01" data-source-id="E01" aria-labelledby="heading-E01"&gt;&lt;h3 id="heading-E01"&gt;[E01] Disruptions in Availability of Peritoneal Dialysis and Intravenous Solutions from Baxter International Facility in North Carolina&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US Centers for Disease Control and Prevention&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2024-10-12&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Event in September to October 2024&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; HAN 00518 Summary and Recommendations&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Documents the North Cove supply interruption and potential care effects.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Does not quantify national financial losses or prove the purchasing incentives proposed in the analysis.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Government health advisory&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.cdc.gov/han/2024/han00518.html" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E02" data-source-id="E02" aria-labelledby="heading-E02"&gt;&lt;h3 id="heading-E02"&gt;[E02] FDA Roundup: October 11, 2024&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US Food and Drug Administration&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2024-10-11&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; 2024-10-11 regulatory announcement&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; First bullet and following product list&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Identifies three additional inadequate-supply products following Helene.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; A historical shortage announcement does not establish current shortage status.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Government announcement&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.fda.gov/news-events/press-announcements/fda-roundup-october-11-2024" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E03" data-source-id="E03" aria-labelledby="heading-E03"&gt;&lt;h3 id="heading-E03"&gt;[E03] Hurricane Helene Summary&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Baxter International&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-05-13&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; September 2024 to May 2025&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Opening statement and recovery paragraphs&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Reports flood damage, February production recovery and May inventory recovery with most IV allocations removed.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Company-reported milestones; not an independent audit of every hospital&amp;#x27;s inventory. Production and inventory milestones are separate.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company first party recovery statement&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.baxter.com/news-insights/hurricane-helene-summary" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E04" data-source-id="E04" aria-labelledby="heading-E04"&gt;&lt;h3 id="heading-E04"&gt;[E04] Global spending on health: Emerging from the pandemic&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; World Health Organization&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2024-12-09&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; 2022 historical baseline&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Printed page 3 PDF page 17 Figure 1.1 and footnotes 1 and 2&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; US$9.8 trillion current health expenditure in 2022; capital excluded. Relevant aggregates cover 190 WHO Member States.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Historical reference, not the latest GHED observation or 2026 market size. Relevant pages were read from the downloaded original PDF. No current global growth rate is inferred.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official statistical report&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.who.int/publications/i/item/9789240104495" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt; · &lt;a href="https://iris.who.int/server/api/core/bitstreams/6a22149b-17d5-4afb-a89b-14a3e8c12442/content" target="_blank" rel="noopener"&gt;Publisher download&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E05" data-source-id="E05" aria-labelledby="heading-E05"&gt;&lt;h3 id="heading-E05"&gt;[E05] National Health Expenditure Accounts Table 2 and NHE Fact Sheet&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US Centers for Medicare and Medicaid Services&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Fact sheet last modified 2026-06-24; table is the 1960 to 2024 historical release&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Calendar 2024 United States&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Table 2 Amount in Billions 2024 column rows 4 7 9 and 16; Fact Sheet Historical NHE 2024&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Total 5278.6; hospital 1634.7; physician and clinical 1109.7; retail prescription drugs 467.0, all US$bn. NHE growth 7.2%. Supports Figure 2.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Includes investment. Retail drugs exclude medicines embedded in service spending. Residual includes all remaining NHE categories. The original workbook was downloaded and its values read, rather than using a rounded $5.3tn denominator.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official national accounts&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt; · &lt;a href="https://www.cms.gov/files/zip/nhe-tables.zip" target="_blank" rel="noopener"&gt;Publisher download&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E06" data-source-id="E06" aria-labelledby="heading-E06"&gt;&lt;h3 id="heading-E06"&gt;[E06] 2025年我国卫生健康事业发展统计公报 China Health Statistics Bulletin 2025&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; National Health Commission of China; official PDF hosted by Shanxi Health Commission&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; NHC release dated 2026-08-28; provincial PDF hosted August 2026&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; 2025 China&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Printed page 1 hospital counts; page 6 Table 4; pages 7 to 8 hospital diagnosis and treatment visits and Table 5&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Preliminary health expenditure and diagnosis/treatment activity; hospital counts and visits by ownership. Supports Figure 4.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Expenditure is a preliminary estimate. Visits are encounters, not unique people. Hospital subgroups and all-institution totals have different scopes. NHC HTML could not be fully retrieved; the complete government-hosted original bulletin PDF was read.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official statistical bulletin accessed through government hosted copy&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://wjw.shanxi.gov.cn/zfxxgk/fdzdgknr/ghjh/202608/P020260831335869219767.pdf" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt; · &lt;a href="https://www.nhc.gov.cn/guihuaxxs/c100132/202608/3fadb2a3da314bb688e848598f6ac6df.shtml" target="_blank" rel="noopener"&gt;Publisher page&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E07" data-source-id="E07" aria-labelledby="heading-E07"&gt;&lt;h3 id="heading-E07"&gt;[E07] Medicare Advantage in 2026: Enrollment Update and Key Trends&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; KFF&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-06-05&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; March 2026 United States Medicare Advantage&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Section on enrollment concentration Figure 6 and its methods note&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Published rounded parent-organization enrollment shares used in Figure 3.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; KFF&amp;#x27;s analysis was read; CMS microdata were not independently reaggregated. Other is a DEX residual from rounded leading shares and may differ from a raw-count aggregation. Not healthcare revenue shares.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Original KFF analysis of CMS administrative data&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.kff.org/medicare/medicare-advantage-in-2026-enrollment-update-and-key-trends/" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E08" data-source-id="E08" aria-labelledby="heading-E08"&gt;&lt;h3 id="heading-E08"&gt;[E08] Thermo Fisher Scientific Inc. Form 10-K for the year ended December 31, 2025&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Thermo Fisher Scientific filing with SEC&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026 filing; exact filing day not relied upon&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Year ended 2025-12-31&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Item 1 Business Segments and Products printed pages 3 to 4&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Laboratory tools, clinical research, development and manufacturing services support its functional placement.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Business descriptions are company disclosures. Corporate revenue includes non-healthcare activities; no industry share or third-party supply relationship is claimed.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company regulatory filing&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E09" data-source-id="E09" aria-labelledby="heading-E09"&gt;&lt;h3 id="heading-E09"&gt;[E09] Annual Report 2025 One Lonza Strategy&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Lonza&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026 annual report for 2025; section undated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; 2025 with clearly identified forward plans&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Expanding capability and capacity and Vacaville integration paragraphs&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Supports CDMO capability examples and disclosed Vacaville integration and customer agreements.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Capabilities and selected agreements do not imply contracts with all mapped companies. Forward capacity plans are not current sales.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company annual report&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.lonza.com/annualreport/2025/company/one-lonza-strategy" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E10" data-source-id="E10" aria-labelledby="heading-E10"&gt;&lt;h3 id="heading-E10"&gt;[E10] Eli Lilly and Company Form 10-K for the year ended December 31, 2025&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Eli Lilly filing with SEC&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-02-12&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Year ended 2025-12-31&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Executive Overview printed page 43; Revenue and product table page 49; Consolidated Statements of Operations&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Product examples; annual income ratios; disclosed growth decomposition and product revenues for the concentration calculation.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Company-wide annual figures, not an industry average or proof of future profitability. The DEX ratio retains the reported income definition.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company regulatory filing&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E11" data-source-id="E11" aria-labelledby="heading-E11"&gt;&lt;h3 id="heading-E11"&gt;[E11] Capital Markets Day 2025&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Siemens Healthineers&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-11-17&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Strategy announced November 2025&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Announcement bullets on Imaging Precision Therapy and Diagnostics&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Supports imaging diagnostics and therapy-equipment examples and announced regrouping.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; A strategy announcement does not establish realized future growth. No segment growth target is presented as an observed outcome.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company strategy announcement&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.siemens-healthineers.com/press/features/cmd2025" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E12" data-source-id="E12" aria-labelledby="heading-E12"&gt;&lt;h3 id="heading-E12"&gt;[E12] Key Facts and Global Impact&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Medtronic&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Live page; no publication date displayed&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Page states FY26 information&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Three portfolios of solutions&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Cardiovascular medical surgical and neuroscience portfolios support device placement.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Self-description, not independent supplier ranking or a comprehensive therapy taxonomy.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company business description&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.medtronic.com/en-us/our-company/key-facts.html" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E13" data-source-id="E13" aria-labelledby="heading-E13"&gt;&lt;h3 id="heading-E13"&gt;[E13] McKesson Corporation Form 10-K for the fiscal year ended March 31, 2026&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; McKesson filing with SEC&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026 filing; exact filing day not relied upon&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Fiscal year ended 2026-03-31&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Item 1 North American Pharmaceutical; Financial Review segment operating profit margin table; Note 20&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Distribution and logistics role; North American Pharmaceutical segment operating profit margin 1.09%.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Fiscal period and segment operating measure differ from calendar-year group net margins. Not a whole-distribution-industry average.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company regulatory filing&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E14" data-source-id="E14" aria-labelledby="heading-E14"&gt;&lt;h3 id="heading-E14"&gt;[E14] HCA Healthcare Reports Fourth Quarter 2025 Results and Provides 2026 Guidance&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; HCA Healthcare&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-01-27&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Year ended 2025-12-31&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Year ended December 31 2025 paragraph and Operating Statistics&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Provider example; US$75600m revenue and US$6784m net income attributable to HCA.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; The ratio uses attributable net income. It is not a pure hospital segment margin or a healthcare-wide average. Forecasts in the release are not used as outcomes.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company results announcement&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://investor.hcahealthcare.com/news/news-details/2026/HCA-Healthcare-Reports-Fourth-Quarter-2025-Results-and-Provides-2026-Guidance/default.aspx" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E15" data-source-id="E15" aria-labelledby="heading-E15"&gt;&lt;h3 id="heading-E15"&gt;[E15] UnitedHealth Group Reports 2025 Results and Issues 2026 Outlook&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; UnitedHealth Group&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-01-27&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Year ended 2025-12-31&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Consolidated results paragraph; site description of UnitedHealthcare and Optum&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; US$447.6bn revenue and reported 2.7% net margin; insurance and services positioning.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Consolidated group measure includes multiple businesses and financial flows. It is not an insurance-only margin or supplier market share.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Company results announcement&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.unitedhealthgroup.com/newsroom/2026/2026-01-27-uhg-reports-2025-results-and-issues-2026-outlook.html" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E16" data-source-id="E16" aria-labelledby="heading-E16"&gt;&lt;h3 id="heading-E16"&gt;[E16] Tracking universal health coverage: 2025 global monitoring report&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; World Health Organization and World Bank&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-12-05&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Service coverage 2023; financial hardship 2022&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; WHO report landing page overview&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; 4.6bn not fully covered and 2.1bn experiencing financial hardship, with distinct data years.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Estimates use revised indicators; groups overlap and cannot be added. Landing-page summary was read, not the entire monitoring report.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official monitoring summary&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.who.int/teams/health-financing-and-economics/global-monitoring-report/2025" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E17" data-source-id="E17" aria-labelledby="heading-E17"&gt;&lt;h3 id="heading-E17"&gt;[E17] Health workforce&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; World Health Organization&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Live topic page; publication day not displayed&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Projection for 2030&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Overview first paragraphs&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Projected 11m health-worker shortfall and explanation of financing and distribution constraints.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Projection rather than an observed current shortage; primarily low- and lower-middle-income settings. Not doctors alone.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official workforce assessment&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.who.int/health-topics/health-workforce" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E18" data-source-id="E18" aria-labelledby="heading-E18"&gt;&lt;h3 id="heading-E18"&gt;[E18] Ageing and health&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; World Health Organization&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-10-01&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Projection for 2030&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Overview population paragraph&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; One in six globally aged 60 years or older by 2030.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Demographic projection is not a commercial market forecast and does not imply uniform care needs.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official demographic fact sheet&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.who.int/news-room/fact-sheets/detail/ageing-and-health" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E19" data-source-id="E19" aria-labelledby="heading-E19"&gt;&lt;h3 id="heading-E19"&gt;[E19] DRG DIP 2.0 policy explanation July 2024&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; National Healthcare Security Administration of China&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2024-07-23&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Historical 2024 policy example&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Section on main contents and exceptional case review&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Explains grouping reform and exceptional-case review relevant to payment incentives.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Used only as a dated mechanism example; not represented as the latest applicable grouping. Local rules and later revisions require separate review.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official policy explanation&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.nhsa.gov.cn/art/2024/7/23/art_105_13316.html" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E20" data-source-id="E20" aria-labelledby="heading-E20"&gt;&lt;h3 id="heading-E20"&gt;[E20] List of Artificial Intelligence-Enabled Medical Devices&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US Food and Drug Administration&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Live list read 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Authorizations identified in the current published list&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Contents of the AI Enabled Medical Devices List&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; List purpose and explicit non-comprehensive limitation.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Does not report deployment revenue reimbursement or general superiority. No device count is used as a market size.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Regulator maintained device list and methods&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.fda.gov/medical-devices/artificial-intelligence-enabled-medical-devices/list-artificial-intelligence-enabled-medical-devices" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E21" data-source-id="E21" aria-labelledby="heading-E21"&gt;&lt;h3 id="heading-E21"&gt;[E21] Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US Food and Drug Administration&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026; exact release day not relied upon&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; 2026 discussion paper&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; About the Discussion Paper status paragraphs&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Topics include risk premarket evaluation and monitoring; explicitly neither draft nor final guidance.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Not a new binding rule or a general authorization. The page was read; the full discussion PDF was not independently reviewed.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Regulator discussion document landing page&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.fda.gov/medical-devices/digital-health-center-excellence/considerations-regulation-generative-ai-enabled-medical-devices-discussion-paper-and-request" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E22" data-source-id="E22" aria-labelledby="heading-E22"&gt;&lt;h3 id="heading-E22"&gt;[E22] Parts of Medicare&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US Centers for Medicare and Medicaid Services Medicare.gov&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Live public information page; no publication day displayed&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Definition read on 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Your Medicare options and Medicare Advantage also known as Part C&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Defines Medicare Advantage and distinguishes it from Original Medicare.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Program explanation, not enrollment shares, revenue or a recommendation to select a plan.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official program explanation&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.medicare.gov/basics/get-started-with-medicare/medicare-basics/parts-of-medicare" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E23" data-source-id="E23" aria-labelledby="heading-E23"&gt;&lt;h3 id="heading-E23"&gt;[E23] 国家医保局按病种付费3.0版分组方案新闻发布会实录 Official press conference on DRG DIP version 3.0&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; National Healthcare Security Administration of China&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-09-02&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; September 2026 policy announcement and mechanism explanation&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Opening announcement; answer on payment standards and retention of savings; exceptional-case review&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Version 3.0 announcement and explanation of group-based standards, savings and treatment of individual cases.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; The original HTML was downloaded and read because web text retrieval timed out. The transcript does not substitute for local payment schedules or the signed contract; no implementation deadline is asserted here.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official press conference transcript&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-26&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.nhsa.gov.cn/art/2026/9/2/art_14_21978.html" target="_blank" rel="noopener"&gt;Original source&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;</description></item></channel></rss>